COVID Vaccines: US FDA Seeks Panel Vote On New Formulation Targeting JN.1 Variant

 
• By Sue Sutter

But agency wants discussion on considerations for the selection of a specific JN.1 lineage strain, such as the KP.2 subvariant, for the 2024-2025 formulation. Although JN.1 sublineages were predominant in the spring, KP.2 is now the most prevalent circulating strain in the US.

Global
Recent epidemiology in the US could complicate the global drive for alignment on COVID-19 vaccine formulations. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers